Publications by authors named "Catherine Sebban"

Claim this Profile
V
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Carla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S Hochster, Catherine Sebban

Blood· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Catherine Sebban

Blood· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.
Arthur Dony, Amine Belhabri, Yves Bertrand, Catherine Sebban, Pascale Cony-Makhoul

J Adolesc Young Adult Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Nicolas Mounier, Sabine Anthony, Raphaël Busson, Catherine Thieblemont, Vincent Ribrag, Catherine Sebban

Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Catherine Sebban

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABVD or BEACOPP along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.
Christophe Fermé, José Thomas, Pauline Brice, Olivier Casasnovas, Andrej Vranovsky, Catherine Sebban

Eur J Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
Marc P E André, Théodore Girinsky, Massimo Federico, Oumédaly Reman, Catherine Fortpied, Catherine Sebban

J Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Emanuele Zucca, Annarita Conconi, Giovanni Martinelli, Reda Bouabdallah, Alessandra Tucci, Catherine Sebban

J Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].
Sabine Anthony, Pierre Hebel, André Garrel, Vanina Oliveri, Catherine Thieblemont, Catherine Sebban

Bull Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Gaëlle Fossard, Céline Ferlay, Emmanuelle Nicolas-Virelizier, Philippe Rey, François Ducray, Catherine Sebban

Eur J Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
Matthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, Stephen M Ansell, Grzegorz S Nowakowski, Catherine Sebban

Am J Hematol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, Hans Gunter Derigs, Sergey Kravchenko

Br J Haematol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Olivier Hermine, Eva Hoster, Jan Walewski, André Bosly, Stephan Stilgenbauer, Catherine Sebban

Lancet· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
David Sibon, Franck Morschhauser, Matthieu Resche-Rigon, David Ghez, Jehan Dupuis, Catherine Sebban

Haematologica· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Benoit You, Gilles Salles, Emmanuel Bachy, Olivier Casasnovas, Hervé Tilly, Catherine Sebban

Cancer Chemother Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Emmanuelle Nicolas-Virelizier, Céline Ségura-Ferlay, Herve Ghesquières, Catherine Chassagne-Clément, Thérèse Gargi, Catherine Sebban

Hematol Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, James R Cerhan, Pierre Biron, Catherine Sebban

J Clin Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.
André Bosly, Andrew Grigg, Harald Holte, Christian Gisselbrecht, John Radford, Catherine Sebban

Oncologist· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, Cyrille Hulin, Gerald Marit, Catherine Sebban

Haematologica· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
John M M Raemaekers, Marc P E André, Massimo Federico, Theodore Girinsky, Reman Oumedaly, Catherine J Sebban

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban

Haematologica· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Emmanuel Bachy, Roch Houot, Franck Morschhauser, Anne Sonet, Pauline Brice, Catherine Sebban

Haematologica· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Lionel Perrier, Anne Lefranc, David Pérol, Philippe Quittet, Aline Schmidt-Tanguy, Catherine Sebban

Appl Health Econ Health Policy· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Bruno Royer, Lavinia Merlusca, Julie Abraham, Lucile Musset, Julien Haroche, Catherine Sebban

Am J Hematol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Emanuele Zucca, Annarita Conconi, Daniele Laszlo, Armando López-Guillermo, Reda Bouabdallah, Catherine Sebban

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis